A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Latest Information Update: 03 Jun 2025
At a glance
- Drugs ALN-CIDEB (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 29 May 2025 Status changed from not yet recruiting to recruiting.
- 28 Feb 2025 New trial record